Disclaimer: This information is intended for educational purposes and should not be considered medical advice. Clinical decisions must be made by qualified healthcare professionals based on individual patient circumstances, current medical evidence, and local guidelines. This reference is not a substitute for professional medical judgment.

---

Viral

(Note: Due to the vastness of the "Viral" topic, this comprehensive reference will focus specifically on Influenza, a common and clinically significant acute viral respiratory infection, to illustrate the detailed structure requested. The principles and structure can be applied to other viral diseases.)

Overview

• Definition: Influenza is an acute viral respiratory illness caused by influenza viruses, primarily types A and B, that infect the respiratory tract. It can range from mild to severe, and in some cases, lead to death.
• Epidemiology:
  • Incidence: Globally, seasonal influenza epidemics result in about 1 billion cases, 3-5 million severe cases, and 290,000 to 650,000 respiratory deaths annually.
  • Demographics: Affects all age groups, but severe outcomes and complications are more common in specific high-risk groups including young children (<5 years, especially <2 years), adults aged ≥65 years, pregnant women, and individuals with underlying chronic medical conditions or immunocompromised states.
  • Transmission: Primarily via respiratory droplets produced when infected persons cough, sneeze, or talk. Can also be transmitted via direct contact with respiratory secretions or fomites.
  • Seasonality: In temperate regions, influenza activity typically peaks in winter months. In tropical regions, influenza can occur year-round.
• Classification: Influenza viruses belong to the family Orthomyxoviridae.
  • Types:
    • Influenza A: Circulates in humans and animals (e.g., birds, pigs). Subtyped based on two surface proteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Examples include H1N1, H3N2. Responsible for pandemics.
    • Influenza B: Primarily circulates among humans. Not classified into subtypes but into two lineages: B/Victoria and B/Yamagata.
    • Influenza C: Causes mild respiratory illness, not associated with epidemics.
    • Influenza D: Primarily affects cattle, not known to infect humans.

Pathophysiology

• Mechanism:
  1. Entry: Influenza virus particles enter the host via inhalation of respiratory droplets.
  2. Attachment: Viral hemagglutinin (HA) binds to sialic acid receptors on the surface of ciliated epithelial cells in the respiratory tract (nose, throat, bronchi, lungs).
  3. Replication: The virus enters the cell, uncoats, and uses host cell machinery to replicate its genetic material (RNA) and proteins. New viral particles are assembled.
  4. Release: New virions bud from the host cell membrane, aided by neuraminidase (NA) which cleaves sialic acid residues, allowing progeny virions to escape and spread.
  5. Immune Response: Infection leads to local inflammation, cellular damage, and systemic symptoms (fever, myalgia) due to cytokine release (e.g., IL-6, TNF-alpha, IFN-alpha/beta). Viral replication and immune response can impair mucociliary clearance, increasing susceptibility to secondary bacterial infections.
• Risk Factors:
  • Age: Children <5 years (especially <2 years) and adults ≥65 years.
  • Underlying Medical Conditions: Chronic pulmonary disease (e.g., asthma, COPD), cardiovascular disease (except isolated hypertension), renal, hepatic, neurologic/neurodevelopmental, hematologic, or metabolic disorders (e.g., diabetes mellitus).
  • Immunosuppression: HIV/AIDS, cancer, organ transplant, chronic corticosteroid use.
  • Pregnancy: Especially in the second and third trimesters, and up to 2 weeks postpartum.
  • Obesity: BMI ≥40.
  • Ethnicity: American Indians/Alaska Natives have higher rates of hospitalization.
  • Nursing Home/Long-term Care Facility Residence: Increased exposure and risk of severe outcomes.
• Protective Factors:
  • Vaccination: Annual influenza vaccination significantly reduces the risk of infection, severe illness, hospitalization, and death.
  • Hand Hygiene: Frequent hand washing with soap and water or alcohol-based hand sanitizer.
  • Respiratory Etiquette: Covering coughs and sneezes.
  • Avoidance of Close Contact: Especially with symptomatic individuals during peak season.
  • Antiviral Prophylaxis: Post-exposure prophylaxis for high-risk individuals.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Abrupt onset of:
  • Fever (often high, >38°C or 100.4°F)
  • Chills
  • Headache
  • Myalgia (muscle aches, often severe)
  • Malaise (fatigue, weakness)
  • Non-productive cough
  • Sore throat
  • Rhinitis (runny or stuffy nose)
• Early Signs: Sudden onset of constitutional symptoms (fever, body aches, fatigue) followed shortly by respiratory symptoms.
• Advanced Signs:
  • Persistent high fever
  • Dyspnea or shortness of breath
  • Chest pain
  • Confusion or altered mental status
  • Cyanosis (bluish discoloration of lips/face)
  • Signs of secondary bacterial pneumonia (e.g., productive cough with purulent sputum, worsening dyspnea after initial improvement)
  • Exacerbation of chronic underlying conditions.
• Atypical Presentations:
  • Children: Gastrointestinal symptoms (nausea, vomiting, diarrhea) are more common than in adults. Otitis media is a frequent complication. May present with febrile seizures.
  • Elderly/Immunocompromised: May have minimal or no fever, or present with only generalized weakness, confusion, or functional decline without prominent respiratory symptoms.

Physical Examination

• Inspection:
  • Flushed face, watery eyes.
  • Signs of respiratory distress (tachypnea, accessory muscle use, nasal flaring in children).
  • General malaise, lethargy.
• Palpation:
  • Warm skin consistent with fever.
  • Cervical lymphadenopathy may be present but usually mild.
• Special Tests:
  • Auscultation of Lungs: Usually clear initially or may reveal scattered rhonchi or crackles from inflammation. Wheezing can occur, especially in those with underlying reactive airway disease. Findings suggesting pneumonia (rales, egophony, diminished breath sounds) warrant further investigation.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and duration of symptoms? (Abrupt onset suggests influenza).
  • Specific symptoms: Fever (documented temperature?), chills, myalgia, cough (productive/non-productive), sore throat, headache, fatigue, GI symptoms.
  • Travel history? Recent exposure to sick contacts? (especially those with confirmed influenza).
  • Vaccination status (influenza vaccine)?
  • Underlying chronic medical conditions, immunosuppression, pregnancy?
  • Medications, allergies.
  • Smoking history.
  • Functional status (e.g., able to perform usual activities, signs of dehydration).
• Red Flags:
  • Dyspnea or shortness of breath at rest or with minimal exertion.
  • Chest pain or pressure.
  • Severe or persistent vomiting.
  • Dizziness, confusion, or sudden onset of altered mental status.
  • Seizures.
  • Severe muscle pain or weakness.
  • Worsening of chronic medical conditions.
  • Cyanosis.
  • Signs of dehydration.
  • In children: fast breathing, difficulty breathing, bluish skin color, not drinking enough fluids, not waking up or interacting, being so irritable that they do not want to be held, flu-like symptoms improve but then return with fever and worse cough.

Laboratory Tests

• First-Line:
  • Clinical Diagnosis: Often made based on classic symptoms during periods of known influenza activity, especially in unvaccinated individuals or those with high-risk exposure.
  • Rapid Influenza Diagnostic Tests (RIDTs): Antigen detection tests. Point-of-care. Results in 10-15 minutes. Sensitivity ranges from 50-70%, specificity >90%. High false-negative rate, especially if viral load is low. Positive result supports diagnosis, but negative result does not rule out influenza. Not recommended for guiding antiviral treatment decisions in high-risk patients.
  • Rapid Molecular Assays (NAATs/RT-LAMP): Nucleic acid amplification tests. Detect viral RNA. Point-of-care. Results in 15-30 minutes. Higher sensitivity (80-95%) and specificity (>95%) than RIDTs. Increasingly preferred for rapid diagnosis.
• Confirmatory:
  • Reverse Transcription Polymerase Chain Reaction (RT-PCR): Gold standard for influenza diagnosis. Highly sensitive (>95%) and specific (>98%). Can differentiate between influenza types (A/B) and subtypes (e.g., H1N1, H3N2), and detect other respiratory viruses. Results may take several hours to a day. Recommended for hospitalized patients, those with severe illness, or for epidemiologic surveillance.
• Monitoring:
  • Complete Blood Count (CBC): May show leukopenia, lymphopenia, or normal WBC count. Leukocytosis may suggest secondary bacterial infection.
  • C-Reactive Protein (CRP) / Procalcitonin: Non-specific inflammatory markers. Elevated in severe infection. Procalcitonin can help differentiate viral from bacterial infection but is not definitive.
  • Blood Cultures: If secondary bacterial infection (e.g., bacteremia, bacterial pneumonia) is suspected.

Imaging

• Recommended:
  • Chest X-ray (CXR): Indicated for patients with signs of lower respiratory tract infection (e.g., dyspnea, hypoxemia, focal lung findings on exam, persistent fever).
    • Typical findings in uncomplicated influenza: Normal or peribronchial thickening, increased interstitial markings.
    • Typical findings in primary viral pneumonia: Bilateral, patchy, or diffuse interstitial infiltrates, often confluent. Less common but more severe.
    • Typical findings in secondary bacterial pneumonia: Lobar consolidation, effusions, cavitations.
• Advanced:
  • Computed Tomography (CT) of Chest: If CXR is inconclusive, or to better characterize infiltrates, effusions, or rule out other causes of respiratory distress (e.g., pulmonary embolism) in severe cases. May show ground-glass opacities, consolidation, or nodular opacities.

Management

Acute Management

• Immediate:
  • Isolate Patient: Implement droplet precautions (surgical mask for patient, healthcare provider wears mask, eye protection, gown, gloves).
  • Assess Severity: Triage for signs of severe illness, respiratory distress, or hypoxemia.
  • Supportive Care: Antipyretics (acetaminophen, NSAIDs), analgesics, rest, adequate hydration.
• Stabilization:
  • Oxygen Therapy: If SpO2 <92% (or patient dependent on baseline), initiate supplemental oxygen to maintain SpO2 ≥92%.
  • Fluid Management: IV fluids for dehydration if oral intake is insufficient.
  • Antiviral Treatment: Initiate empiric antiviral therapy as soon as possible (ideally within 48 hours of symptom onset) for patients with suspected or confirmed influenza who are:
    • Hospitalized (any severity).
    • Have severe, complicated, or progressive illness (e.g., pneumonia, respiratory failure, sepsis).
    • Are in a high-risk group for influenza complications (see Risk Factors above), regardless of hospitalization status.
    • Preferred Agents (CDC/IDSA guidelines):
      • Oseltamivir (Tamiflu): Oral.
        • Adults/adolescents: 75 mg BID for 5 days.
        • Children: Dosing based on weight (e.g., <15kg: 30mg BID; 15-23kg: 45mg BID; 23-40kg: 60mg BID; >40kg: 75mg BID).
        • Renal impairment: Adjust dose based on creatinine clearance.
      • Zanamivir (Relenza): Inhaled. Not for patients with underlying respiratory disease (e.g., asthma, COPD) due to bronchospasm risk.
        • Adults/children ≥7 years: 2 inhalations (10 mg) BID for 5 days.
      • Peramivir (Rapivab): Intravenous. Single dose.
        • Adults: 600 mg IV over 15-30 minutes.
      • Baloxavir marboxil (Xofluza): Oral. Single dose.
        • Adults/children ≥12 years weighing 40-80 kg: 40 mg PO once.
        • Adults/children ≥12 years weighing >80 kg: 80 mg PO once.
        • Not recommended for pregnant or breastfeeding women due to limited data.
• Emergency:
  • Acute Respiratory Failure: Intubation and mechanical ventilation for hypoxemic or hypercapnic respiratory failure. Consider non-invasive ventilation cautiously.
  • Septic Shock: Fluid resuscitation, vasopressors, broad-spectrum antibiotics (if bacterial superinfection suspected).
  • ARDS Management: Lung-protective ventilation strategies (low tidal volume, PEEP).
  • ECMO (Extracorporeal Membrane Oxygenation): For refractory hypoxemia in severe ARDS, especially in younger, otherwise healthy patients.

Chronic Management

• Pharmacological:
  • Management of Complications:
    • Secondary Bacterial Pneumonia: Empiric broad-spectrum antibiotics (e.g., ceftriaxone plus azithromycin or doxycycline; consider vancomycin if MRSA suspected or severe illness). Adjust based on culture results.
    • Exacerbation of Chronic Conditions: Optimize management of underlying conditions (e.g., increase bronchodilators for asthma/COPD).
  • Post-Influenza Syndrome: No specific pharmacological treatment. Management is symptomatic (e.g., analgesics for persistent myalgia).
• Non-pharmacological:
  • Rest and Gradual Return to Activity: Encourage rest during acute illness and gradual resumption of normal activities to prevent post-viral fatigue.
  • Nutritional Support: Ensure adequate nutrition and hydration.
  • Pulmonary Rehabilitation: For patients with significant post-influenza lung injury or weakness.
  • Psychological Support: For anxiety or depression associated with prolonged illness or severe outcomes.
• Monitoring:
  • Resolution of Symptoms: Track fever, cough, and other symptoms.
  • Oxygen Saturation: Monitor SpO2 until stable and without supplemental oxygen.
  • Laboratory Markers: Repeat CBC, CRP, or procalcitonin if concern for ongoing infection or complications.
  • Radiographic Follow-up: Repeat CXR if pneumonia symptoms persist or worsen.

Treatment Algorithms

• First-Line:
  1. Suspected/Confirmed Influenza + High-Risk or Severe/Complicated Illness: Empiric oral Oseltamivir (75 mg BID for 5 days) initiated ASAP, preferably within 48 hours of symptom onset.
  2. Uncomplicated Influenza in Low-Risk Outpatients: Symptomatic care (rest, hydration, antipyretics). Antivirals typically not indicated unless clinical judgment suggests benefit.
• Second-Line:
  1. If Oseltamivir resistance is suspected/confirmed (rare) or not tolerated, consider Zanamivir (inhaled) or Peramivir (IV).
  2. Baloxavir marboxil (single oral dose) is an alternative to Oseltamivir, particularly for non-hospitalized patients aged ≥12 years who are otherwise healthy or at high risk for complications, and within 48 hours of symptom onset.
• Refractory Cases:
  • Failure to Respond to Antivirals: Consider prolonged course of antivirals (e.g., 10 days of Oseltamivir for immunocompromised or severely ill patients).
  • Antiviral Resistance: Test for antiviral resistance (neuraminidase inhibition assay). If resistance to NAIs is detected, consider Baloxavir (if sensitive) or supportive care.
  • Severe ARDS: May require advanced respiratory support (e.g., high-frequency oscillatory ventilation, prone positioning, ECMO).
  • Persistent Secondary Bacterial Infection: Evaluate for resistant organisms, deep-seated infection, or other complications.

Complications

• Common:
  • Secondary Bacterial Pneumonia: Most common serious complication, often due to Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), or Haemophilus influenzae.
  • Otitis Media: Especially in children.
  • Sinusitis:
  • Exacerbation of Chronic Diseases: Asthma, COPD, heart failure, diabetes.
• Serious:
  • Primary Influenza Viral Pneumonia: Severe, rapidly progressive pneumonia directly caused by the virus, leading to ARDS and respiratory failure.
  • Acute Respiratory Distress Syndrome (ARDS): Leading cause of death in severe influenza.
  • Myocarditis/Pericarditis: Inflammation of the heart muscle/sac.
  • Encephalitis/Meningitis: Inflammation of the brain/meninges (rare but severe).
  • Rhabdomyolysis: Muscle breakdown, potentially leading to renal failure.
  • Toxic Shock Syndrome: Usually secondary to Staphylococcus aureus superinfection.
  • Sepsis/Septic Shock: From primary viral infection or secondary bacterial infection.
  • Guillain-Barré Syndrome: Post-infectious demyelinating neuropathy (rare).
  • Reye's Syndrome: Rare but severe complication in children given aspirin during viral illness.
• Long-term:
  • Post-viral Fatigue Syndrome: Persistent fatigue, malaise, and cognitive difficulties after acute illness.
  • Chronic Lung Injury: In patients who developed severe pneumonia or ARDS.
  • Psychological Sequelae: PTSD, depression, anxiety in survivors of severe critical illness.

Prognosis

• Factors:
  • Age: Extremes of age (very young, very old) are associated with worse prognosis.
  • Underlying Health Conditions: Presence of chronic cardiovascular, pulmonary, metabolic, renal, hepatic, neurologic conditions, or immunosuppression significantly worsens prognosis.
  • Vaccination Status: Vaccinated individuals generally have milder illness and lower risk of complications.
  • Timeliness of Antiviral Treatment: Early treatment (within 48 hours) improves outcomes, especially in high-risk patients.
  • Viral Strain: Certain influenza strains (e.g., pandemic H1N1, avian H5N1) may be associated with higher severity.
  • Development of Complications: Secondary bacterial pneumonia, ARDS, myocarditis are indicators of poorer prognosis.
• Survival:
  • Uncomplicated Influenza: Excellent prognosis, most recover fully within 1-2 weeks.
  • Hospitalized Cases: Mortality rate can range from 1-10%, higher in ICU patients (10-30%) and those with ARDS.
  • Global Estimates: 290,000 to 650,000 respiratory deaths annually globally attributed to seasonal influenza.
• Quality of Life:
  • Most individuals fully recover with no long-term impact.
  • Severe cases, especially those requiring ICU admission, may experience prolonged recovery, persistent fatigue, weakness, cognitive impairment, and reduced quality of life for months.
  • Patients with pre-existing conditions may experience a permanent decline in functional status.

Prevention

• Primary:
  • Annual Influenza Vaccination: The most effective primary prevention strategy.
    • Recommendation: Recommended for everyone aged ≥6 months annually, with rare exceptions.
    • Types: Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV).
    • Timing: Ideally before influenza activity begins in the community, typically by end of October in temperate climates.
  • Hand Hygiene: Frequent hand washing with soap and water or alcohol-based hand sanitizer (at least 60% alcohol).
  • Respiratory Etiquette: Cover coughs and sneezes with a tissue or into the elbow.
  • Avoidance: Minimize close contact with sick individuals.
• Secondary:
  • Antiviral Chemoprophylaxis: May be considered for high-risk individuals after close exposure to a confirmed influenza case, when vaccination is not feasible or effective (e.g., severely immunocompromised).
    • Agents: Oseltamivir (75 mg once daily for 7 days), Zanamivir (10 mg once daily for 10 days).
    • Duration: Typically 7-10 days after last exposure.
  • Early Diagnosis and Treatment: Prompt identification of influenza in high-risk groups allows for timely antiviral treatment, which can reduce severity and risk of complications.
• Tertiary:
  • Management of Complications: Prompt and appropriate treatment of secondary bacterial infections (e.g., pneumonia, sepsis) and other complications to reduce morbidity and mortality.
  • Rehabilitation: Physical and occupational therapy for patients recovering from severe illness to prevent long-term functional deficits.
  • Chronic Disease Management: Optimal control of underlying chronic medical conditions to minimize impact of influenza.

Special Populations

• Pediatric:
  • Higher Risk: Children <5 years (especially <2 years) are at higher risk for complications and hospitalization.
  • Presentation: May have more GI symptoms (vomiting, diarrhea). Febrile seizures are possible.
  • Treatment: Oseltamivir is approved for treatment in infants >14 days and for prophylaxis in infants >3 months. Dosing is weight-based.
  • Vaccination: Annual vaccination recommended for all children ≥6 months. LAIV (nasal spray) is an option for healthy non-pregnant individuals aged 2-49 years without underlying conditions.
• Geriatric:
  • Higher Risk: Adults ≥65 years are at significantly higher risk for severe illness, hospitalization, and death due to immunosenescence and higher prevalence of comorbidities.
  • Presentation: May present atypically with weakness, confusion, functional decline, rather than prominent fever or respiratory symptoms.
  • Vaccination: Higher-dose (Fluzone High-Dose Quadrivalent) or adjuvanted (Fluad Quadrivalent) influenza vaccines are preferentially recommended for this age group as they elicit a stronger immune response.
• Pregnancy:
  • Higher Risk: Pregnant women (and up to 2 weeks postpartum) are at increased risk for severe illness, hospitalization, and adverse pregnancy outcomes (e.g., preterm labor, fetal distress).
  • Treatment: Oseltamivir is the preferred antiviral for pregnant women due to extensive safety data. Treatment should be initiated as soon as possible.
  • Vaccination: Inactivated influenza vaccine (IIV) is strongly recommended at any stage of pregnancy during influenza season. It protects both the mother and provides passive immunity to the infant for the first few months of life. LAIV is contraindicated.
• Comorbidities:
  • Immunocompromised: Prolonged viral shedding, increased risk of severe and prolonged illness. May require extended antiviral treatment courses. Vaccination efficacy may be reduced.
  • Chronic Lung/Heart Disease: Higher risk of severe exacerbations and complications (e.g., pneumonia, heart failure). Aggressive treatment and close monitoring are crucial.
  • Morbid Obesity: Increased risk of severe influenza, hospitalization, and death.

Clinical Pearls

• Diagnostic:
  • "Flu-like Illness" during season: In peak influenza season, a patient with abrupt onset of fever, myalgia, and respiratory symptoms can often be diagnosed clinically, especially in low-risk individuals where specific testing may not alter management.
  • Don't trust the negative RIDT: A negative rapid influenza diagnostic test (RIDT) does not rule out influenza, especially during peak season or in high-risk patients. Clinical suspicion and RT-PCR should guide decision-making for antivirals.
  • Test to treat, not just to confirm: Diagnostic testing is most useful when results will influence clinical management (e.g., initiation of antivirals, infection control measures, co-infection diagnosis).
• Treatment:
  • "Time is Tamiflu": For high-risk or severely ill patients, initiate empiric antiviral treatment (Oseltamivir) as soon as possible, ideally within 48 hours of symptom onset. Do not wait for lab confirmation. The benefit of antivirals decreases substantially after 48 hours but can still be considered for hospitalized patients or those with progressive illness, even after 48 hours.
  • Symptomatic Management is Key: For most healthy individuals with uncomplicated influenza, supportive care (rest, fluids, antipyretics) is sufficient. Antivirals provide modest benefit and are generally reserved for high-risk groups.
  • Antivirals are not antibiotics: Do not use antivirals to treat bacterial co-infections. If bacterial co-infection is suspected, appropriate antibiotics are needed.
• Pitfalls:
  • Over-reliance on RIDTs: Missing influenza in high-risk patients due to a false-negative RIDT and consequently delaying antiviral treatment.
  • Under-treatment of Complications: Failure to recognize and treat secondary bacterial pneumonia or other severe complications aggressively.
  • Aspirin in Children: Never give aspirin or aspirin-containing products to children or adolescents with viral illnesses due to the risk of Reye's Syndrome.
  • Misinterpreting CXR: Early viral pneumonia may not show significant changes on CXR; repeat imaging or clinical reassessment may be needed.
  • Vaccine Hesitancy: Underestimating the severity of influenza and the importance of annual vaccination.

Recent Updates

• Guidelines:
  • CDC/ACIP Recommendations: Annual updates to influenza vaccine recommendations and guidance on antiviral use based on circulating strains and emerging evidence. Always consult the latest CDC Advisory Committee on Immunization Practices (ACIP) recommendations.
  • IDSA Guidelines: Infectious Diseases Society of America (IDSA) periodically updates guidelines for the diagnosis and treatment of influenza. Latest is 2018, with periodic updates to drug recommendations.
• Evidence:
  • Baloxavir Marboxil (Xofluza): Approval in 2018 (US) provided a novel single-dose antiviral option with a different mechanism of action (inhibiting cap-dependent endonuclease), offering an alternative to neuraminidase inhibitors. Studies show similar efficacy to oseltamivir for uncomplicated influenza.
  • High-Dose/Adjuvanted Vaccines: Continued emphasis and preferential recommendation for high-dose or adjuvanted influenza vaccines in older adults due to superior immunogenicity and efficacy compared to standard-dose vaccines.
  • Universal Vaccination: Growing evidence supports the benefit of universal annual influenza vaccination for reducing disease burden, complications, and healthcare utilization.
• Controversies:
  • Optimal Antiviral Duration in Severe Cases: Debate on whether extended courses of antivirals (e.g., >5 days) are beneficial for severely ill or immunocompromised patients, despite common practice.
  • Antiviral Resistance Surveillance: Ongoing concern about the emergence and spread of antiviral resistance, especially to oseltamivir, though currently rare.
  • N95 vs. Surgical Masks: Ongoing debate regarding optimal personal protective equipment for healthcare workers managing influenza, with growing evidence suggesting surgical masks may be sufficient for routine care, but N95s for aerosol-generating procedures.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC): Influenza (Flu) pages (www.cdc.gov/flu) for current season recommendations, vaccine guidance, and antiviral treatment algorithms.
  • Advisory Committee on Immunization Practices (ACIP): Recommendations for preventing and controlling influenza. Published annually in MMWR.
  • Infectious Diseases Society of America (IDSA): 2018 Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza.
  • World Health Organization (WHO): Global Influenza Programme (www.who.int/influenza) for global surveillance and recommendations.
• Studies:
  • Original Research on Antiviral Efficacy: Landmark trials supporting the efficacy of oseltamivir, zanamivir, peramivir, and baloxavir (e.g., studies published in NEJM, Lancet ID).
  • Vaccine Effectiveness Studies: Annual studies published by CDC and other public health agencies evaluating the effectiveness of the current season's vaccine.
• Reviews:
  • Comprehensive reviews on influenza pathophysiology, epidemiology, and management from major medical journals (e.g., Lancet, NEJM, JAMA).
  • Cochrane Reviews on influenza vaccine and antiviral efficacy.